AzTrials
AzTrials

MetabolismACCUMULATENCT05647135

ImpACt of Very High Protein Content Enteral nUtrition Formulas on Critically Ill MUltipLe trAuma paTiEnts

An observational study of Metabolism and Trauma, run by Romanian Society for Enteral and Parenteral Nutrition at 1 site in Romania.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This prospective observational randomized study aims to determine energy, protein intake and gastrointestinal tolerance while using enteral nutrition formulas with very high protein content and enteral nutrition formulas with normal protein content. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Metabolism, Trauma, Nutritional Deficiency
What is being tested?
Medical food
How many people
70 participants
Where
1 siteRomania
Study dates
1 Mar 2023to 1 Dec 2024
How long will I take part?
8 Weeks
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Consecutive patients with multiple trauma intubated and mechanical ventilated, admitted to the intensive care unit (ICU)

Who may be able to join

  • Adult patients (>18 yrs) admitted to the ICU
  • Multiple trauma (Injury severity score > 18)
  • Intubation and mechanical ventilation upon admission in ICU or during the first 24 hours of admission, for at least 48 h

Who cannot join

  • Age < 18 years
  • Pregnant women
  • Patients not intubated or not mechanically ventilated or receiving only non-invasive ventilation
  • Patients with enteral feeding contraindication 48 h after admission
  • Patients with recent gastrointestinal surgical intervention
  • Patients on chronic therapy with corticosteroids

Trial locations and contacts

1 site in 1 country.

Ioana Grintescu, MD, PhD contact

+40722329187

ioana.grintescu@rospen.ro

Cristian Cobilinschi, MD, PhD contact

+40765018776

cristian.cobilinschi@umfcd.ro

Romania1 site, 1 recruiting
  • Clinical Emergency Hospital of Bucharest

    Bucharest

    Ioana Grințescu, Professor, +40722329187, ioana.grintescu@rospen.ro

    Cristian Cobilinschi, MD, PhD, +40765018776, cristian.cobilinschi@umfcd.ro

    Recruiting

Other trials in Romania

About this study

Official title: ImpACt of Very High Protein Content Enteral nUtrition Formulas on Protein Metabolism and Residual Gastric Volume in Critically Ill MUltipLe trAuma paTiEnts

This prospective observational randomized study aims to determine energy, protein intake and gastrointestinal tolerance while using enteral nutrition formulas with very high protein content and enteral nutrition formulas with normal protein content.

  • Differences regarding achieving protein and calorie daily targets when using enteral nutrition formulas with different protein content
  • Differences regarding residual gastric volume when using enteral nutrition formulas with different protein content
  • Differences regarding body composition when using enteral nutrition formulas with different protein content
Read the detailed description

ImpACt of very high protein Content enteral nUtrition formulas on protein metabolism and residual gastric volume in critically ill MUltipLe trAuma paTiEnts

  • ACCUMULATE trial -

Background and rationale:

Despite an increased survival among critically ill patients, many of the ICU "survivors" may develop prolonged functional disabilities. It has already been proven that nutritional therapy is essential, considering that an adequate provision of calories and proteins may influence patients prognostic.

Multiple trauma patients are on a particular nutritional risk, since their high nitrogen demands and associated nutritional therapy challenges, caused by repeated surgical intervention or multiple imagistic procedures. Although nutritional therapy impact on mortality is still in debate, clear, positive results were obtained in decreasing ICU and hospital stay after adequate nutritional support.

According to ESPEN guideline on clinical nutrition in the ICU early enteral nutrition (within 48 h) should be initiated in order to assure an adequate calorie and protein intake. Beside optimal timing, the management of nutrition therapy in critically ill patients should also integrate the optimal route and caloric/protein targets.

Energy requirements monitoring through indirect calorimetry has been proposed as a standard-of-care method for critically ill patients, considering its proven superiority towards predictive equation.

Beyond calorie intake, proteins proved to play a central role in maintain lean body mass, healing wounds and supporting immune function.For multiple trauma patients it was reported that protein losses may reach 14 % of the total body stores, thus this type of patients are exposed to a particular increased risk of protein deficits. If calorie administration benefits from a proper monitoring tool, protein requirements are still based on predictive equation. The impact of protein administration is also lacking of direct measurements techniques. Lean body mass evaluation by ultrasound and computerized tomography has been reported to have a good correlation with hospital stay and pots-ICU functional capacity. Moreover muscle function evaluation through a hand-grip dynamometer was also tested with good results in patients with ARDS.

Source of administered protein may also influence nitrogen balance, considering that whey proteins (rich in leucine) promote a slower hydrolysis and allow a longer period for absorption.

Reaching the recommended goals is often impeded by gastric intolerance manifested through increased gastric volume residues. It has been already demonstrated that large gastric volume residues are associated with impaired absorption and an increased incidence of aspiration pneumonia.

Gastrointestinal dysfunction in multiple trauma patients admitted to the intensive care unit (ICU) is an important yet underrecognized consequence. There are various causes of gastrointestinal tract dysfunction mostly related to patients general health condition and to their diagnostics. Gastrointestinal failure may be induced by several factors like immunological, biological and mechanical barrier disruption and it may be manifested through stress ulceration, bacterial translocation, ileus, intra-abdominal hypertension, diarrhoea and constipation.

Whether residual gastric volume monitoring should be regularly performed has been extensively discussed. Although the results from some randomised trials which focused on monitoring gastric residual volume, did not find any difference in outcomes, this measurement was far for being abandoned. Moreover, gastric residual volume monitoring is still an essential component of enteral nutrition patient care.

Although several monitoring methods for gastric volume residue measurements were described, there is no generally accepted technique for daily use.

Objective:

This prospective observational randomized study aims to determine energy, protein intake and gastrointestinal tolerance while using enteral nutrition formulas with very high protein content and enteral nutrition formulas with normal protein content.

Safety points:

  • Clinical parameters - vomiting, diarrhoea
  • Biochemical parameters - base excess, urea levels
  • Daily gastric residual volume evaluation using ultrasound gastric antrum measurements after 24 hours of continuous enteral nutrition administration using both types of formulas;

Study population Consecutive patients with multiple trauma intubated and mechanical ventilated, admitted to the intensive care unit (ICU).

Sample size calculation Since the hypotheses of the study are exploratory, no formal sample size calculation has been performed. This prospective observational study aims to recruit>70 multiple trauma patients.

Randomization:

Simple randomization method will be used to assign subjects into two groups A and B.

Ethical considerations:

This study will be conducted in full conformity with the Declaration of Helsinki and Good Clinical Practices.

Local ethical committee approval will be asked before any patient will be included.

Considering that nutritional support has become a standard-of-care in every intensive care unit in the world, it is considered that this research is based on collecting data routinely available for every critically ill patient. Although no intervention is performed an informed consent will be provided.

Taking into account that the included patients are not able to provide informed consent at the time of recruitment (on ICU admission), a Power of Attorney or a Legal tutor will act as Consultee and will be asked to consent/decline participation to the study on legal behalf of the patient. If patients have Advance Decision Plan including participation in research studies the Plan will be respected and recruitment pursued/abandoned accordingly.

After regaining capacity, all patients will be asked to provide Informed Consent for using their personal data and will be given the possibility to:

Provide Informed Consent for the acute data and follow-up. Deny research participation and request destruction of acute data collected.

Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to the Data Manager and the Statistician of the study.

Expected impact of the study KNOWLEDGE The investigators aim to provide a detailed description of protein administration using two different types of enteral formulas. The main objectives of the study are to evaluate energy, protein intake and gastrointestinal tolerance while using enteral nutrition formulas with different protein content. Nevertheless, the investigators want to provide data about the impact of these different enteral nutrition formulas on body composition as well as on functionality.

Regarding of the obtained data a change on local and national recommendation considering enteral nutrition in multiple trauma patients is to be expected.

Funding All the enteral nutrition products are donated by the Nutricia Global. No funding will be received for this study.

Being tested
Medical food
Keywords
enteral nutrition, multiple trauma, energy target, protein target, body composition, gastric residual volume, enteral nutrition intolerance
Medical subject headings
Wounds and Injuries, Malnutrition, Kwashiorkor, Gastroparesis, Muscular Atrophy, Protein-Energy Malnutrition, Multiple Trauma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Medical foodOther

    enteral formulas with different protein composition

Study groups in NCT05647135
Study groupRoleWhat they receive
Group AGroup A - enteral formula with 6.3 g/100 ml protein
Receives: Other: Medical food
Group Benteral formula with 10 g/100 ml protein
Receives: Other: Medical food

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Calorie and protein target

    Differences regarding achieving protein and calorie daily targets in grams per kilogram of body weight (g/kg BW) at day 5 of the intervention period and at day 10 when using enteral nutrition formulas with different protein content

    Measured: on day 5 days

  2. Calorie and protein target

    Differences regarding achieving protein and calorie daily targets in grams per kilogram of body weight (g/kg BW) at day 5 of the intervention period and at day 10 when using enteral nutrition formulas with different protein content

    Measured: on day 10

Secondary outcomes (18)
  1. Ultrasound-guided assessment of gastric residual volume

    Differences regarding residual gastric volume when using enteral nutrition formulas with different protein content.

    Ultrasound assessment of gastric volume using a current model for GV assessment based on antral cross-sectional area (CSA) - GV (ml)1⁄427.0+14.6×right-lateral CSA (cm2)21.28×age (yr)

    Measured: on day 5

  2. Ultrasound-guided assessment of gastric residual volume

    Differences regarding residual gastric volume when using enteral nutrition formulas with different protein content.

    Ultrasound assessment of gastric volume using a current model for GV assessment based on antral cross-sectional area (CSA) - GV (ml)1⁄427.0+14.6×right-lateral CSA (cm2)21.28×age (yr)

    Measured: on day 10

  3. Muscle function

    Muscle function evaluation using handgrip dynamometer after extubation and sedation cessation

    Measured: 24 hours after extubation

  4. Muscle function

    Muscle function evaluation using handgrip dynamometer after extubation and sedation cessation

    Measured: 5 days after extubation

  5. Body composition - Fat-free body mass

    Fat-free body mass assessment using bioelectrical impedance analysis

    Measured: 24 hours after extubation

  6. Body composition - Fat-free body mass

    Fat-free body mass assessment using whole-body bioelectrical impedance

    Measured: 5 days after extubation

  7. Body composition - Total body water

    Total body water assessment using whole-body bioelectrical impedance analysis

    Measured: 24 hours after extubation

  8. Body composition - Total body water

    Total body water assessment using whole-body bioelectrical impedance analysis

    Measured: 5 days after extubation

  9. Body composition - Phase angle

    Phase angle measurement using whole-body bioelectrical impedance analysis

    Measured: 24 hours after extubation

  10. Body composition - Phase angle

    Phase angle measurement using whole-body bioelectrical impedance analysis

    Measured: 5 days after extubation

  11. Body composition - ultrasound

    Quadriceps rectus femoris thickness thickness measured by B-mode ultrasonography

    Measured: baseline (on admission/first 24 hours)

  12. Body composition - ultrasound

    Quadriceps rectus femoris thickness measured by B-mode ultrasonography

    Measured: on day 5

  13. Body composition - ultrasound

    Quadriceps rectus femoris thickness measured by B-mode ultrasonography

    Measured: on day 10

  14. Body composition - ultrasound

    Quadriceps rectus femoris thickness measured by B-mode ultrasonography

    Measured: on day 15

  15. Inflammation - CRP

    Plasmatic levels of C-reactive protein

    Measured: on day 5

  16. Inflammation - CRP

    Plasmatic levels of C-reactive protein

    Measured: on day 10

  17. Inflammation - prealbumin

    Plasmatic levels of prealbumin

    Measured: on day 5

  18. Inflammation - prealbumin

    Plasmatic levels of prealbumin

    Measured: on day 10

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Dec 2022
  2. Study start1 Mar 2023
  3. Primary completion1 Dec 2024 (estimated)
  4. Study completion1 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
70 participants (estimated)
Target duration
8 Weeks
IDs, dates and publications
ClinicalTrials.gov ID
NCT05647135
Sponsor's protocol ID
rospen9accumulate
Acronym
ACCUMULATE
Status last verified
Jul 2024
First submitted
1 Nov 2022
Last updated
22 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data requests can be submitted by researchers in the field of clinical nutrition starting 9 months after article publication and the data will be made accessible for up to 3 years. Extensions will be considered on a case-by-case basis

Publications

  • van Zanten ARH, Petit L, De Waele J, Kieft H, de Wilde J, van Horssen P, Klebach M, Hofman Z. Very high intact-protein formula successfully provides protein intake according to nutritional recommendations in overweight critically ill patients: a double-blind randomized trial. Crit Care. 2018 Jun 12;22(1):156. doi: 10.1186/s13054-018-2070-5.

    PubMed 29895309
  • Singer P. Protein metabolism and requirements in the ICU. Clin Nutr ESPEN. 2020 Aug;38:3-8. doi: 10.1016/j.clnesp.2020.03.026. Epub 2020 May 31.

    PubMed 32690175
  • Tedeschi-Jockers F, Reinhold S, Hollinger A, Tuchscherer D, Kiss C, Gantner L, Ledergerber K, Zimmermann S, Scheuzger J, Huber J, Siegemund M. A new high protein-to-energy enteral formula with a whey protein hydrolysate to achieve protein targets in critically ill patients: a prospective observational tolerability study. Eur J Clin Nutr. 2022 Mar;76(3):419-427. doi: 10.1038/s41430-021-00956-9. Epub 2021 Jun 24.

    PubMed 34168292
  • Berger MM, Reintam-Blaser A, Calder PC, Casaer M, Hiesmayr MJ, Mayer K, Montejo JC, Pichard C, Preiser JC, van Zanten ARH, Bischoff SC, Singer P. Monitoring nutrition in the ICU. Clin Nutr. 2019 Apr;38(2):584-593. doi: 10.1016/j.clnu.2018.07.009. Epub 2018 Jul 20.

    PubMed 30077342
  • Yasuda H, Kondo N, Yamamoto R, Asami S, Abe T, Tsujimoto H, Tsujimoto Y, Kataoka Y. Monitoring of gastric residual volume during enteral nutrition. Cochrane Database Syst Rev. 2021 Sep 27;9(9):CD013335. doi: 10.1002/14651858.CD013335.pub2.

    PubMed 34596901

Questions about this trial

What is this clinical trial studying?

An observational study of Metabolism and Trauma, run by Romanian Society for Enteral and Parenteral Nutrition at 1 site in Romania.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ioana Grintescu, MD, PhD (+40722329187, ioana.grintescu@rospen.ro), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Calorie and protein target (time frame: on day 5 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05647135, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in